Top ▲

Chronic idiopathic urticaria

Disease ID:1232
Name:Chronic idiopathic urticaria
Associated with:0 target
2 immuno-relevant ligands
Description
A condition characterised by frequent and recurrent wheals and itching with no known cause.

Targets

No target related data available for Chronic idiopathic urticaria

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
omalizumab
Immuno Disease Comments: An anti-IgE therapy approved to treat antihistamine-resistant chronic idiopathic urticaria .
Clinical Use: Used to treat moderate to severe IgE-mediated (i.e. allergy triggered) persistent asthma (US) or severe asthma (EU) [1], in adults and children over 12 years old, inadequately controlled by inhaled corticosteroid treatment. In 2014 the US FDA approved use of this drug for the treatment of chronic idiopathic urticaria (CIU, a.k.a. chronic spontaneous urticaria) which is unresponsive to treatment with anti-histamine H1 receptor drugs.
In July 2016, the FDA expanded asthma approval to include children six to 11 years of age, as indicated previously for those 12 years-adult. | View clinical data
loratadine
Immuno Disease Comments: Antihistamine approved for CIU.
Clinical Use: Loratidine is used to relieve the symptoms of allergic rhinitis and chronic idiopathic urticaria. | View clinical data

References

Show »

1. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol., 108 (2): 184-90. [PMID:11496232]